BRPI0514413C1 - sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento - Google Patents
sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamentoInfo
- Publication number
- BRPI0514413C1 BRPI0514413C1 BRPI0514413A BRPI0514413A BRPI0514413C1 BR PI0514413 C1 BRPI0514413 C1 BR PI0514413C1 BR PI0514413 A BRPI0514413 A BR PI0514413A BR PI0514413 A BRPI0514413 A BR PI0514413A BR PI0514413 C1 BRPI0514413 C1 BR PI0514413C1
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- medicine
- pharmaceutical composition
- biphenyl compound
- purification process
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 7
- 235000010290 biphenyl Nutrition 0.000 title abstract 2
- 239000004305 biphenyl Substances 0.000 title abstract 2
- -1 biphenyl compound Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- QMOVGVNKXUTCQU-UHFFFAOYSA-N (2-phenylphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 QMOVGVNKXUTCQU-UHFFFAOYSA-N 0.000 abstract 1
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000005980 lung dysfunction Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60180504P | 2004-08-16 | 2004-08-16 | |
| US60/601,805 | 2004-08-16 | ||
| PCT/US2005/029013 WO2006023454A1 (en) | 2004-08-16 | 2005-08-15 | Crystalline form of a biphenyl compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0514413A BRPI0514413A (pt) | 2008-06-10 |
| BRPI0514413B1 BRPI0514413B1 (pt) | 2019-04-16 |
| BRPI0514413C1 true BRPI0514413C1 (pt) | 2021-05-25 |
Family
ID=35687428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514413A BRPI0514413C1 (pt) | 2004-08-16 | 2005-08-15 | sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7521558B2 (https=) |
| EP (1) | EP1778672B1 (https=) |
| JP (2) | JP5032990B2 (https=) |
| KR (1) | KR101363352B1 (https=) |
| CN (1) | CN101006077B (https=) |
| AR (1) | AR051003A1 (https=) |
| AU (1) | AU2005277601B2 (https=) |
| BR (1) | BRPI0514413C1 (https=) |
| CA (1) | CA2575874C (https=) |
| DK (1) | DK1778672T3 (https=) |
| ES (1) | ES2400958T3 (https=) |
| HR (1) | HRP20130192T1 (https=) |
| IL (1) | IL180853A (https=) |
| MA (1) | MA28825B1 (https=) |
| MX (1) | MX2007001688A (https=) |
| MY (1) | MY141224A (https=) |
| NO (1) | NO338770B1 (https=) |
| NZ (1) | NZ552796A (https=) |
| PL (1) | PL1778672T3 (https=) |
| PT (1) | PT1778672E (https=) |
| RU (1) | RU2381223C2 (https=) |
| SI (1) | SI1778672T1 (https=) |
| TW (1) | TWI374883B (https=) |
| WO (1) | WO2006023454A1 (https=) |
| ZA (1) | ZA200701057B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| WO2008041095A1 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Limited | Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| JP5540075B2 (ja) * | 2009-04-14 | 2014-07-02 | グラクソ グループ リミテッド | ビフェニル−２−イルカルバミン酸エステルの調製方法 |
| AU2015234331B2 (en) * | 2009-04-23 | 2017-08-03 | Theravance Biopharma R&D Ip, Llc | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| MX2011011156A (es) * | 2009-04-23 | 2011-11-04 | Theravance Inc | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| CA2852912A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Intellectual Property Limited | Pazopanib formulation |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TW201835041A (zh) | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
| US11484531B2 (en) | 2018-08-30 | 2022-11-01 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
| WO2022175982A1 (en) * | 2021-02-19 | 2022-08-25 | Gbr Laboratories Private Limited | A process for preparing batefenterol and intermediates thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS596860B2 (ja) * | 1975-05-19 | 1984-02-15 | オオツカセイヤク カブシキガイシヤ | ５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法 |
| TW297025B (https=) * | 1992-02-14 | 1997-02-01 | Squibb & Sons Inc | |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| DE60021282T2 (de) | 1999-12-07 | 2006-05-18 | Theravance, Inc., South San Francisco | Carbamat-derivate als muscarin-rezeptor antonisten |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP2004356517A (ja) | 2003-05-30 | 2004-12-16 | Ebara Corp | 基板洗浄装置及び基板洗浄方法 |
| US20050025718A1 (en) | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
-
2005
- 2005-08-03 TW TW094126435A patent/TWI374883B/zh not_active IP Right Cessation
- 2005-08-08 AR ARP050103308A patent/AR051003A1/es active IP Right Grant
- 2005-08-15 AU AU2005277601A patent/AU2005277601B2/en not_active Ceased
- 2005-08-15 BR BRPI0514413A patent/BRPI0514413C1/pt not_active IP Right Cessation
- 2005-08-15 WO PCT/US2005/029013 patent/WO2006023454A1/en not_active Ceased
- 2005-08-15 HR HRP20130192TT patent/HRP20130192T1/hr unknown
- 2005-08-15 MX MX2007001688A patent/MX2007001688A/es active IP Right Grant
- 2005-08-15 US US11/204,065 patent/US7521558B2/en active Active
- 2005-08-15 DK DK05803280.6T patent/DK1778672T3/da active
- 2005-08-15 KR KR1020077005834A patent/KR101363352B1/ko not_active Expired - Fee Related
- 2005-08-15 JP JP2007527919A patent/JP5032990B2/ja not_active Expired - Fee Related
- 2005-08-15 CN CN2005800281254A patent/CN101006077B/zh not_active Expired - Fee Related
- 2005-08-15 CA CA2575874A patent/CA2575874C/en not_active Expired - Lifetime
- 2005-08-15 MY MYPI20053814A patent/MY141224A/en unknown
- 2005-08-15 PT PT58032806T patent/PT1778672E/pt unknown
- 2005-08-15 PL PL05803280T patent/PL1778672T3/pl unknown
- 2005-08-15 NZ NZ552796A patent/NZ552796A/en not_active IP Right Cessation
- 2005-08-15 ES ES05803280T patent/ES2400958T3/es not_active Expired - Lifetime
- 2005-08-15 RU RU2007109598/04A patent/RU2381223C2/ru active
- 2005-08-15 SI SI200531675T patent/SI1778672T1/sl unknown
- 2005-08-15 EP EP05803280A patent/EP1778672B1/en not_active Expired - Lifetime
-
2007
- 2007-01-22 IL IL180853A patent/IL180853A/en active IP Right Grant
- 2007-02-05 ZA ZA200701057A patent/ZA200701057B/xx unknown
- 2007-02-23 MA MA29717A patent/MA28825B1/fr unknown
- 2007-03-09 NO NO20071307A patent/NO338770B1/no unknown
-
2009
- 2009-02-11 US US12/369,605 patent/US8101766B2/en not_active Expired - Fee Related
-
2011
- 2011-12-16 US US13/328,386 patent/US8476299B2/en not_active Expired - Fee Related
-
2012
- 2012-03-22 JP JP2012065767A patent/JP2012121929A/ja not_active Withdrawn
-
2013
- 2013-06-05 US US13/910,708 patent/US8754223B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0514413C1 (pt) | sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento | |
| WO2007127297A3 (en) | Crystalline forms of a dimethylphenyl compound | |
| BRPI0906104A2 (pt) | "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" | |
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| WO2001028996A3 (en) | Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases | |
| EP1887007A3 (en) | Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors | |
| BRPI0707559B8 (pt) | polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos | |
| BRPI0410117A (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto | |
| WO2008068615A8 (en) | Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid | |
| WO2010033444A8 (en) | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor | |
| BRPI0517567A (pt) | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| TW200714586A (en) | Crystalline forms of a biphenyl compound | |
| IL193771A (en) | Preparations that act as protein inhibitors deliver cholesterol ester | |
| MA32564B1 (fr) | NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
| MY151229A (en) | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | |
| BR9909870A (pt) | Pirrolidinas como inibidores de neuraminidases | |
| WO2005123670A3 (en) | Crystalline form of a substituted pyrrolidine compound | |
| BRPI0519152A2 (pt) | composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica | |
| WO2008053295A3 (en) | Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid | |
| WO2008121817A3 (en) | Quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition | |
| MA28990B1 (fr) | Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| TH82585A (th) | โครงรูปผลึกของสารประกอบไบฟีนิล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: THERAVANCE RESPIRATORY COMPANY, LLC (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2519 DE 16/04/2019, QUANTO A DATA DA PRIORIDADE UNIONISTA. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2788 DE 11-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |